Efficacy of Prostate Biopsies via Transperineal and Transrectal Routes for Significant Prostate Cancer Detection: A Multicenter Paired–Matched Study

Otros/as autores/as

Institut Català de la Salut

[Paesano N] Clínica Creu Blanca, Barcelona, Spain. Department of Surgery, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Picola N] Department of Urology, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain. [Muñoz-Rodriguez J] Department of Urology, Hospital Universitari Parc Tauli, Sabadell, Spain. [Ruiz-Plazas X] Department of Urology, Hospital Universitari Joan XXIII, Tarragona, Spain. [Muñoz-Rivero MV] Department of Urology, Hospital Universitari Arnau de Vilanova, Lleida, Spain. [Celma A] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Miró B] Unitat d’Estadística i Bioinformàtica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Trilla E, Morote J] Department of Surgery, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Fecha de publicación

2025-03-31T10:05:40Z

2025-03-31T10:05:40Z

2025-01-26



Resumen

Prostate biopsy; Prostate cancer; Transperineal


Biòpsia de pròstata; Càncer de pròstata; Transperineal


Biopsia de próstata; Cáncer de próstata; Transperineal


Background: A transperineal approach to prostate biopsy is now recommended to reduce the risk of infectious complications associated with the transrectal route. Our aim is to compare the efficacy of transrectal- and transperineal-guided biopsies involving the magnetic resonance imaging (MRI) of index lesions in detecting significant prostate cancer (sPCas), and to evaluate the role of systematic biopsies. Methods: In a prospective and multicenter trial conducted in an opportunistic early detection program for sPCa in Catalonia (Spain), between 2021 and 2023, 4029 men suspected of having PCa underwent multiparametric MRI followed by guided and systematic biopsies. From this cohort, we retrospectively selected 1376 men with reports of the size and localization of their index lesions. A matched group of 325 pairs of men subjected to transrectal and transperineal biopsy were chosen to account for confounding variables. We compared sPCa detection rates determined via index lesions and systematic biopsies, as well as by lesion localization. Results: Transperineal and transrectal biopsies detected sPCa in 49.5% vs. 40.6% overall (p = 0.027), 44.6% vs. 30.8% from index lesions (p = 0.001), and 24.3% vs. 35.1% from systematic biopsies (p = 0.003). SPCa detection rates were higher in transperineal biopsies across all index lesion localizations, with significant increases in the anterior zone (47.8% vs. 20.8% at the mid-base, p = 0.039, and 52.9% vs. 24.2% at the apex, p = 0.024) and central zone (33.3% vs. 5.9%, p = 0.003). With regards to SPCa detected only in systematic biopsies, 10.5% of cases were detected in transrectal biopsies and 4.9% of cases were detected in transperineal biopsies (p = 0.012). Conclusions: Targeted biopsies conducted via the transperineal route showed higher sPCa detection rates than transrectal biopsies, particularly for anterior and apical lesions, with systematic biopsies showing reduced utility.


This research was supported by the Instituto de Salut Carlos III (SP) and the European Union (PI20/01666).

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Materias y palabras clave

Avaluació de resultats (Assistència sanitària); Pròstata - Càncer - Diagnòstic; Imatgeria per ressonància magnètica; Biòpsia; DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms; Other subheadings::Other subheadings::/diagnosis; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Tomography::Magnetic Resonance Imaging; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy::Image-Guided Biopsy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata; Otros calificadores::Otros calificadores::/diagnóstico; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::tomografía::imagen por resonancia magnética; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia::biopsia guiada por imágenes; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

Publicado por

MDPI

Documentos relacionados

Diagnostics;15(3)

https://doi.org/10.3390/diagnostics15030288

info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01666

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)